Rare Lyme disease-causing bacteria spotted on routine blood films
Eye on Innovation
Eye on Innovation features exciting advances taking place at Mayo Clinic Laboratories. This monthly series shines a spotlight on recently developed tests and highlights how Mayo Clinic translates ideas and discoveries into testing resources that improve diagnosis and care for patients across the globe.
It’s long been known that Lyme disease is caused by bacteria transmitted through the bite of an infected black-legged tick (otherwise known as the deer tick). The understanding for many years was that one species of bacteria was the main culprit behind Lyme disease in the United States: Borrelia burgdorferi.
But in 2016, researchers at Mayo Clinic discovered a new species of bacteria that causes Lyme disease. They named it Borrelia mayonii, after Mayo Clinic’s founders, Drs. William and Charles Mayo.
The bacterium was revealed through Mayo Clinic Laboratories’ polymerase chain reaction (PCR) blood test for Lyme disease (Test ID: PBORR). That PCR testing is the preferred method for differentiating between the two bacteria. People who have B. mayonii infection also may test positive with the Lyme disease serology test (Test ID: LYME), but the test will not distinguish a B. mayonii infection from a B. burgdorferi infection.
A key difference that has been noted between B. mayonii and B. burgdorferi is that B. mayonii spirochetes are found at high levels in peripheral blood, whereas B. burgdorferi spirochetes are not. Researchers surmised that meant the B. mayonii spirochetes potentially could be found on routine peripheral blood smears.
That proved to be true earlier this year when staff in Mayo Clinic’s Division of Clinical Microbiology observed several spirochaetes on thin blood films from a specimen that had tested PCR positive for B. mayonii. The bacteria were confirmed to be B. mayonii through genome sequencing. The findings were published in July in the journal Clinical Microbiology and Infection.
“It is important for pathologists and laboratorians to know that spirochetes of Borrelia mayonii can occasionally be seen on routine peripheral blood smears,” says Bobbi Pritt, M.D., chair of Mayo’s Division of Clinical Microbiology and the paper’s lead author. “Otherwise, they would probably assume that the spirochetes were from the Borrelia species that cause relapsing fever, which is very different from Lyme disease.”
Because B. mayonii has only been found in the Upper Midwest of the United States, it remains a rare cause of Lyme disease and may frequently go undetected. Understanding that its spirochetes can occasionally be visualized in routine blood films may raise awareness and recognition of the uncommon bacterium, and it could point the way to more consistent and accurate diagnosis of this cause of Lyme disease.
More from Eye on Innovation
A web of innovation within Mayo Clinic Laboratories links research and test development with clinical practice, enabling for some of the world’s most pioneering methodologies. Underpinning this innovation network are unique supports that provide inventive and essential solutions to broaden testing capabilities.
It’s been understood for some time that an infection of B. mayonii, a rare species of bacterium, results in high levels of spirochetes in the peripheral blood. But actually being able to visualize them on a routine peripheral blood smear may allow for improved recognition of this uncommon cause of Lyme disease.
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.